Satellite Bio

Executive Summary

Satellite Bio is a privately held biotechnology company pioneering an off-the-shelf cell therapy for severe liver diseases. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company is developing a novel approach to regenerative medicine by delivering functional hepatocytes to patients with hepatic insufficiency. Their therapy aims to address a significant unmet need where current treatment options are limited. By leveraging an allogeneic cell source, Satellite Bio seeks to provide a readily available, standardized product that can restore liver function without the need for patient-specific customization. The company's platform has the potential to transform the management of acute and chronic liver failure, offering a scalable solution that could reduce dependence on organ transplantation. As a preclinical-stage entity, Satellite Bio is focused on advancing its lead candidate through IND-enabling studies and preparing for first-in-human trials. The company's progress will depend on successful regulatory interactions and securing additional financing to support clinical development.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Cell Therapy Candidate60% success
• Q2 2026Series B or C Financing Round70% success
• Q3 2026Preclinical Data Publication in Peer-Reviewed Journal75% success